History of meeting the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) criteria, or the 1997 ACR criteria, or the 2012 Systemic Lupus International Collaborating Clinics (SLICC)
SLE is in the moderate to severe active phase with the SLEDAI-2000 score ≥ 8
At least one British Isle Lupus Rating Group Index (BILAG-2004) Class A (severe manifestation) or two Class B (moderate manifestation) organ scores, or both
Inadequate response to glucocorticoids and at least 2 of treatments used for at least 3 months
Women of childbearing potential and their partners must agree to use at least 1 highly effective method of contraception throughout the study period and for 1 year after treatment
Signed informed consent
You may not be if
Severe lupus nephritis requiring prohibited medications for active nephritis treatment，or hemodialysis, or eGFR \< 50 ml/min/1.73m²
Central nervous system disease caused by SLE or other conditions
Significant medical history that would pose a risk to the patients safety from the investigator's opinion, or patients medical condition could worsen during the study
Malignancies within 5 years
Presence of active, recurrent, chronic infection requiring treatment , or latent infection (HBV, HCV, HIV, TB, syphilis)
Received any B-cell depletion biologic therapy
Received immunosuppressive small molecule drug therapy， or other systemic corticosteroid therapy ， or prednisone
